System and method for monitoring health using exhaled breath

Abstract

The present invention includes systems and methods for monitoring endogenous compound concentration in blood by detecting markers, such as odors, upon exhalation by a patient, wherein such markers are the endogenous compound itself or result from the endogenous compound. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as “artificial” or “electronic” noses or tongues, to non-invasively monitor endogenous compound levels in blood. The invention further includes a reporting system capable of tracking endogenous compound concentrations in blood (remote or proximate locations) and providing the necessary alerts with regard to emergent or harmful conditions in a patient.

Description

CROSS-REFERENCE TO A RELATED APPLICATION [0001] This application is a continuation-in-part of co-pending International Application No. PCT / US2005 / 006355, filed Feb. 28, 2005, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 10 / 788,501, filed Feb. 26, 2004, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 10 / 178,877, filed Jun. 24, 2002, which is a continuation-in-part of co-pending U.S. patent application Ser. No. 10 / 054,619, filed Jan. 22, 2002. All of the afore-mentioned applications are hereby incorporated by reference herein in their entirety, including any figures, tables, or drawings.FIELD OF INVENTION [0002] The present invention relates to non-invasive monitoring of substance / compound concentrations in blood; and more particularly, to a system and method for the determination of drug concentrations and endogenous compounds in blood utilizing a breath detection system. BACKGROUND INFORMATION [0003] Breath is a unique...

AI Technical Summary

Benefits of technology

[0039] In one embodiment, the subject invention contemplates administering to a patient a therapeutic drug, wherein the therapeutic drug contains a therapeutic drug marker that is detectable in exhaled breath by a sensor of the subject invention. In certain embodiments of the invention, the therapeutic drug marker is the therapeutic drug itself or a metabolite of the drug, which is detectable in exhaled breath. As contemplated herein, the blood concentration of the therapeutic drug and the exhaled concentration of the therapeutic drug marker are substantially proportional. By using a sensor of the subject invention for analyzing the concentration of a therapeutic drug marker in exhaled breath, which substantially corresponds to the blood concentration of a therapeutic drug, the present invention enables non-invasive, continuous monitoring of therapeutic drug blood concentration.

[0048] In one example, a sensor of the subject invention would be used either in a clinical setting or patient-based location during delivery of a therapeutic drug to monitor drug concentration in blood by measuring therapeutic drug marker concentration in patient exhaled breath. Moreover, exhaled breath detection using the systems and methods of the present invention may enable accurate evaluation of PD / PK for drug studies and / or in individual patients.

[0062] A resulting advantage of the subject invention is the ability to monitor such substance and / or therapeutic drug concentration in a more cost effective and frequent manner than current methods, which involve drawing blood samples and transferring the blood samples to a laboratory facility for analysis. In addition, the subject invention enables the user to immediately and continuously monitor therapeutic drug and / or endogenous compound concentration levels in a patient's blood stream to monitor patient health, whether in a clinical setting or via known forms of communication if the patient is located at a remote location. The systems and methods of the subject invention can be used in place of the invasive practice of drawing blood to measure concentration.

Problems solved by technology

It is less likely to be associated with the transfer of serious infections than other bodily fluids and collection of samples is straightforward and painless.

Medications are ineffective if blood concentration levels are too low.

Moreover, certain medications are toxic to the body when concentration levels in the blood are too high.

Although highly effective for the treatment of depression, TCAs have a high incidence of side effects, some of which maybe life-threatening, especially when blood concentrations are too high.

In addition to the toxic effects of TCAs due to inhibition of sodium and potassium channels, which occurs primarily in the heart and brain, TCAs can also cause side effects due inhibition of norepinephrine reuptake and elevated norepinephrine levels.

The latter can cause sedation, manic episodes, profuse sweating, palpitations, increased blood pressure, tachycardia, twitches and tremors of the tongue or upper extremities, and weight gain.

Although SSRIs are no more, or may actually be slightly less effective than TCAs, TCAs are less attractive because they are more toxic than SSRIs and pose a greater threat of overdose.

The greater danger with TCA is that side effects, as well as constant blood sampling, will persuade the patient to discontinue treatment.

Interestingly, recent studies have shown that some SSRIs (and a similar group of drugs—selective norepinephrine uptake inhibitors [SNRIs]) have a “cut-off” below which the drugs are far less effective than at doses above the “cut-off”, but that this can only be determined by blood concentrations, not dosage due to large inter-patient variability.

Thus, many therapeutically effective medications that require TDM are less likely to be prescribed by physicians in view of inconvenience in constant blood sampling and lack of patient compliance.

Further, in the present era of cost-effective healthcare, considerations of prescription costs have become the primary issue for all aspects of laboratory operation.

Currently available tests for TDM are invasive, difficult to administer, frequently require the patient to be in a health care setting (versus home), and / or require an extended period of time for analysis.

Such tests are generally complex, requiring a laboratory to perform the analysis.

Healthcare providers' offices rarely possess appropriate testing technology to analyze blood samples and must therefore send the samples to an off-site laboratory or refer the patient to the laboratory to have their blood drawn, which results in an extended time period for analysis.

In the process of transfer to and from a laboratory, there is a greater likelihood that samples will be lost or mishandled, or that the incorrect results are provided to the healthcare provider, which could be detrimental to the patient's health and well-being.

Further, those on-site test devices that are presently available for assessing drug concentration levels in blood are expensive.

Reference laboratories using sophisticated techniques such as gas chromatography-mass spectrometry typically conduct complex and expensive toxicological analyses to determine the quantity of a medication.

A further problem with present methods of TDM is that the concentration in the blood may not correlate with the concentration at the “effect site”.

The drug concentration at the site of action relates best with clinical responses; however, it is typically difficult or impossible to measure.

Although plasma drug concentrations often provide an informative and feasible measurement for defining the pharmacodynamics of medications, they do not consistently provide an accurate report of drug disposition in a patient.

Although the fraction of drug bound to protein and whole blood is essentially constant over a wide range of plasma and blood concentrations (i.e., free drug concentrations can be deduced from plasma and whole blood concentrations under normal circumstances) for the vast majority of subjects, various pathological circumstances can arise that make this correlation in a patient problematic (e.g., drug-drug interactions, massive blood loss and transfusion, protein losing syndromes, etc).

Because lipid soluble drugs tend to dissolve in fat, drugs can build up to very high, potentially toxic, levels in a patient with a high percentage of body fat.

Protein binding limits the therapeutic effectiveness of the drug.

Membranes such as the blood brain barrier (BBB) sometimes make it difficult for the drug to be properly distributed.

Thus, current methods for analyzing a blood sample to assess plasma drug concentrations only provides a snapshot for defining the pharmacodynamics of a drug and does not consistently provide an accurate report of drug disposition in a patient.

Anesthesiologists use many sophisticated and expensive devices to monitor the vital signs of and to provide respiratory and cardiovascular support for patients undergoing surgical procedures.

Currently, however, volatile anesthetics are seldom used alone.

A major disadvantage of conventional gas monitors is that they only determine the concentrations of certain types of gases or a limited number of gases and most do not measure N2 nor any medications delivered by other routes (i.e., intravenously).

These monitors are also fragile, expensive and require frequent calibration and maintenance.

Unfortunately, these vaporizers frequently go out of calibration and the anesthesiologist may administer too much or too little anesthesia.

At present, a major impediment to the wider use of IV anesthetics, rather than inhaled anesthetics, has been the inability to precisely determine the quantity of drug required to provide a sufficient “depth of anesthesia” without accumulating an excessive amount.

However, even if TCI systems produced the exact target concentrations of blood concentration, it would not be possible to know if that concentration was satisfactory for each individual patient and for different points during the surgical procedure.

However, these technologies are costly and not entirely predictive.

Images